Showing results (501-510 of 989) with videos related to
Sort By:
Pageof 99
Therapeutic Advances in Respiratory Disease|April 30, 2020
Risk factors of non-invasive ventilation failure in hematopoietic stem-cell transplantation patients with acute respiratory distress syndromeJiawei Shen, Yan Hu, Huiying Zhao, et al.Therapeutic Advances in Respiratory Disease|April 30, 2020
Quantitative measurement properties and score interpretation of the Cough Severity Diary in patients with chronic coughAllison Martin Nguyen, Elizabeth Bacci, Peter Dicpinigaitis, et al.Therapeutic Advances in Respiratory Disease|August 25, 2021
Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trialKlaus F Rabe, Fernando J Martinez, Dave Singh, et al.Therapeutic Advances in Respiratory Disease|June 16, 2020
Real-life experience with high-frequency chest wall oscillation vest therapy in adults with non-cystic fibrosis bronchiectasisTara Lynn Barto, Diego Jose Maselli, Sarah Daignault, et al.Therapeutic Advances in Respiratory Disease|January 19, 2022
Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolutionFulvio Braido, Angelo G Corsico, Davide Paleari, et al.Therapeutic Advances in Respiratory Disease|March 15, 2021
Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacyMaria F Acosta, Priya Muralidharan, Carissa L Grijalva, et al.Therapeutic Advances in Respiratory Disease|September 6, 2022
Clinimetric analysis of outcome measures for airway clearance in people with cystic fibrosis: a systematic reviewGemma E Stanford, Mandy Jones, Susan C Charman, et al.Therapeutic Advances in Respiratory Disease|August 29, 2022
Impact of adherence to treatment with inhaled corticosteroids/long-acting β-agonists on asthma outcomes in the United StatesCarlyne M Averell, François Laliberté, Guillaume Germain, et al.Therapeutic Advances in Respiratory Disease|April 23, 2011
NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary diseaseClaus Vogelmeier, Donald BanerjiTherapeutic Advances in Respiratory Disease|May 19, 2011
Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?Michel Aubier, John Haughney, Olof Selroos, et al.Pageof 99